Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    Open Studies | "Hereditary Breast and Ovarian Cancer Syndrome"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting The Women Choosing Surgical Prevention (WISP) Trial
Condition: Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Procedure: Salpingectomy;   Procedure: Oophorectomy;   Behavioral: Questionnaires
2 Recruiting Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Conditions: Breast Cancer;   Hereditary Breast and Ovarian Cancer
Intervention:
3 Recruiting Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
Condition: Hereditary Breast and Ovarian Cancer Syndrome
Intervention: Behavioral: psychoeducation
4 Not yet recruiting Women at Risk of Breast Cancer and OLFM4
Condition: Hereditary Breast and Ovarian Cancer Syndrome
Intervention: Biological: OLFM4
5 Not yet recruiting Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Carcinoma;   Hereditary Breast and Ovarian Cancer Syndrome;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Procedure: Evaluation of Cancer Risk Factors;   Other: Medical Chart Review;   Other: Study of Socioeconomic and Demographic Variables
6 Recruiting Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
Condition: Hereditary Breast and Ovarian Cancer
Intervention: Behavioral: Structured exercise training plus mediterranean diet
7 Recruiting Cancer Genetics Hereditary Cancer Panel Testing
Condition: Hereditary Breast and Ovarian Cancer
Interventions: Other: Questionnaires;   Other: Blood Draw and Baseline Questionnaire
8 Recruiting A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Conditions: Ovarian Cancer;   Breast Cancer;   Prostate Cancer
Intervention: Drug: LY2606368

Indicates status has not been verified in more than two years